About Secretogranin-3
Secretogranin-3 (SCG3) is a protein
from Homo sapiens identified by UniProt accession
Q8WXD2, 468 residues long.
MolForge cross-references it against 0 known binders and
104 disease associations.
Target properties
| Protein name | Secretogranin-3 |
| UniProt accession | Q8WXD2 |
| Gene | SCG3 |
| Organism | Homo sapiens |
| Length | 468 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (104)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.25
- blood protein measurement · score 0.21
- body mass index · score 0.18
- self reported educational attainment · score 0.17
- cognitive function measurement · score 0.17
- developmental and epileptic encephalopathy, 13 · score 0.12
- developmental and epileptic encephalopathy · score 0.12
- schizophrenia · score 0.11
- fat body mass · score 0.10
- body fat percentage · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WXD2-F1 | alphafold | PREDICTED | 59.13 | — |
Amino-acid sequence (468 residues)
MGFLGTGTWI LVLVLPIQAF PKPGGSQDKS LHNRELSAER PLNEQIAEAE EDKIKKTYPP ENKPGQSNYS FVDNLNLLKA ITEKEKIEKE RQSIRSSPLD NKLNVEDVDS TKNRKLIDDY DSTKSGLDHK FQDDPDGLHQ LDGTPLTAED IVHKIAARIY EENDRAVFDK IVSKLLNLGL ITESQAHTLE DEVAEVLQKL ISKEANNYEE DPNKPTSWTE NQAGKIPEKV TPMAAIQDGL AKGENDETVS NTLTLTNGLE RRTKTYSEDN FEELQYFPNF YALLKSIDSE KEAKEKETLI TIMKTLIDFV KMMVKYGTIS PEEGVSYLEN LDEMIALQTK NKLEKNATDN ISKLFPAPSE KSHEETDSTK EEAAKMEKEY GSLKDSTKDD NSNPGGKTDE PKGKTEAYLE AIRKNIEWLK KHDKKGNKED YDLSKMRDFI NKQADAYVEK GILDKEEAEA IKRIYSSL
Explore Secretogranin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets